Your browser doesn't support javascript.
loading
Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment.
Ma, Yun-Ju; Dai, Hai-Ping; Cui, Qing-Ya; Cui, Wei; Zhu, Wen-Juan; Qu, Chang-Ju; Kang, Li-Qing; Zhu, Ming-Qing; Zhu, Xia-Ming; Liu, Dan-Dan; Feng, Yu-Feng; Shen, Hong-Jie; Liu, Tian-Hui; Qiu, Hui-Ying; Yu, Lei; Wu, De-Pei; Tang, Xiao-Wen.
Afiliação
  • Ma YJ; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China.
  • Dai HP; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University Suzhou, Jiangsu, China.
  • Cui QY; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China.
  • Cui W; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University Suzhou, Jiangsu, China.
  • Zhu WJ; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China.
  • Qu CJ; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University Suzhou, Jiangsu, China.
  • Kang LQ; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China.
  • Zhu MQ; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University Suzhou, Jiangsu, China.
  • Zhu XM; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China.
  • Liu DD; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University Suzhou, Jiangsu, China.
  • Feng YF; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China.
  • Shen HJ; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University Suzhou, Jiangsu, China.
  • Liu TH; Shanghai Unicar-Therapy Bio-medicine Technology Co, Ltd Shanghai, China.
  • Qiu HY; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China.
  • Yu L; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University Suzhou, Jiangsu, China.
  • Wu DP; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University Suzhou, Jiangsu, China.
  • Tang XW; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University Suzhou, Jiangsu, China.
Am J Cancer Res ; 12(2): 615-621, 2022.
Article em En | MEDLINE | ID: mdl-35261791
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am J Cancer Res Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am J Cancer Res Ano de publicação: 2022 Tipo de documento: Article